ContributorsPublishersAdvertisers

Onvansertib With FOLFIR/Bevacizumab Induces Responses With Manageable Safety in KRAS-Mutant mCRC

targetedonc.com
 2022-01-22

Cover picture for the articlePhase 1b/2 data for the combination of onvansertib with FOLFIR I and bevacizumab appear promising for paints with KRAS-mutant metastatic colorectal cancer. Onvansertib, an oral, highly selective PLK1 inhibitor, administered with irinotecan, fluorouracil (5-FU), and folinic acid (leucovorin; FOLFIRI) and bevacizumab (Avastin) was well-tolerated in patients with KRAS-mutated metastatic colorectal cancer...

www.targetedonc.com

Comments / 0

Comments / 0